Is INTT or CTKB more profitable?

inTEST has a net margin of 2.33% compared to Cytek Biosciences' net margin of -36.25%. inTEST's return on equity of 5.31% beat Cytek Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets inTEST 2.33% 5.31% 3.42% Cytek Biosciences -36.25% -10.07% -7.56%

Does the media prefer INTT or CTKB?

In the previous week, inTEST had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for inTEST and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat inTEST's score of 0.81 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment inTEST 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FEIM or INTT?

In the previous week, Frequency Electronics had 3 more articles in the media than inTEST. MarketBeat recorded 6 mentions for Frequency Electronics and 3 mentions for inTEST. inTEST's average media sentiment score of 0.81 beat Frequency Electronics' score of 0.76 indicating that inTEST is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Frequency Electronics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive inTEST 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OPTX or INTT?

inTEST has a consensus price target of $19.00, suggesting a potential upside of 37.88%. Given inTEST's stronger consensus rating and higher possible upside, analysts plainly believe inTEST is more favorable than Syntec Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syntec Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 inTEST 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, OPTX or INTT?

inTEST has higher revenue and earnings than Syntec Optics. Syntec Optics is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Syntec Optics $27.53M 10.32 -$1.79M -$0.08 N/A inTEST $121.07M 1.43 $9.34M $0.04 344.50

Is OPTX or INTT more profitable?

inTEST has a net margin of 2.33% compared to Syntec Optics' net margin of -10.95%. inTEST's return on equity of 5.31% beat Syntec Optics' return on equity. Company Net Margins Return on Equity Return on Assets Syntec Optics -10.95% -30.86% -12.35% inTEST 2.33% 5.31% 3.42%

Does the media refer more to OPTX or INTT?

In the previous week, Syntec Optics had 2 more articles in the media than inTEST. MarketBeat recorded 5 mentions for Syntec Optics and 3 mentions for inTEST. Syntec Optics' average media sentiment score of 0.92 beat inTEST's score of 0.81 indicating that Syntec Optics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syntec Optics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive inTEST 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, LAB or INTT?

inTEST has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Standard BioTools $86.26M 3.77 -$74.90M $0.20 4.17 inTEST $121.07M 1.43 $9.34M $0.04 344.50

Does the media favor LAB or INTT?

In the previous week, Standard BioTools had 5 more articles in the media than inTEST. MarketBeat recorded 8 mentions for Standard BioTools and 3 mentions for inTEST. Standard BioTools' average media sentiment score of 0.83 beat inTEST's score of 0.81 indicating that Standard BioTools is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive inTEST 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PRE or INTT?

inTEST has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prenetics Global $120.07M 2.63 -$37.71M -$4.58 N/A inTEST $121.07M 1.43 $9.34M $0.04 344.50

Is PRE or INTT more profitable?

inTEST has a net margin of 2.33% compared to Prenetics Global's net margin of -62.45%. inTEST's return on equity of 5.31% beat Prenetics Global's return on equity. Company Net Margins Return on Equity Return on Assets Prenetics Global -62.45% -20.33% -15.42% inTEST 2.33% 5.31% 3.42%

Does the media favor PRE or INTT?

In the previous week, Prenetics Global had 2 more articles in the media than inTEST. MarketBeat recorded 5 mentions for Prenetics Global and 3 mentions for inTEST. inTEST's average media sentiment score of 0.81 beat Prenetics Global's score of 0.41 indicating that inTEST is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prenetics Global 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral inTEST 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

inTEST (INTT) Competitors

$13.78 -0.92 (-6.26%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$14.20 +0.42 (+3.05%)

As of 07/24/2026 07:34 PM Eastern

Compare

INTT vs. CTKB, FEIM, OPTX, LAB, and PRE

Should you buy inTEST stock or one of its competitors? MarketBeat compares inTEST with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with inTEST include Cytek Biosciences (CTKB), Frequency Electronics (FEIM), Syntec Optics (OPTX), Standard BioTools (LAB), and Prenetics Global (PRE). These companies are all part of the "measuring and control equipment" industry.

How does inTEST compare to Cytek Biosciences?

inTEST (NYSE:INTT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

inTEST has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
inTEST	$121.07M	1.43	$9.34M	$0.04	344.50
Cytek Biosciences	$204.17M	2.82	-$66.54M	-$0.57	N/A

inTEST has a net margin of 2.33% compared to Cytek Biosciences' net margin of -36.25%. inTEST's return on equity of 5.31% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
inTEST	2.33%	5.31%	3.42%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

inTEST presently has a consensus price target of $19.00, indicating a potential upside of 37.88%. Cytek Biosciences has a consensus price target of $5.69, indicating a potential upside of 27.52%. Given inTEST's stronger consensus rating and higher probable upside, analysts plainly believe inTEST is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

63.2% of inTEST shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 5.2% of inTEST shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

inTEST has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

In the previous week, inTEST had 1 more articles in the media than Cytek Biosciences. MarketBeat recorded 3 mentions for inTEST and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat inTEST's score of 0.81 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
inTEST	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

inTEST beats Cytek Biosciences on 10 of the 16 factors compared between the two stocks.

How does inTEST compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and inTEST (NYSE:INTT) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

58.6% of Frequency Electronics shares are held by institutional investors. Comparatively, 63.2% of inTEST shares are held by institutional investors. 28.0% of Frequency Electronics shares are held by insiders. Comparatively, 5.2% of inTEST shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Frequency Electronics had 3 more articles in the media than inTEST. MarketBeat recorded 6 mentions for Frequency Electronics and 3 mentions for inTEST. inTEST's average media sentiment score of 0.81 beat Frequency Electronics' score of 0.76 indicating that inTEST is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Frequency Electronics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
inTEST	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Frequency Electronics presently has a consensus target price of $43.67, suggesting a potential downside of 39.74%. inTEST has a consensus target price of $19.00, suggesting a potential upside of 37.88%. Given inTEST's higher probable upside, analysts clearly believe inTEST is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Frequency Electronics has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, inTEST has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

inTEST has higher revenue and earnings than Frequency Electronics. Frequency Electronics is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$63.23M	11.31	-$900K	-$0.09	N/A
inTEST	$121.07M	1.43	$9.34M	$0.04	344.50

inTEST has a net margin of 2.33% compared to Frequency Electronics' net margin of -1.43%. inTEST's return on equity of 5.31% beat Frequency Electronics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	-1.43%	-1.56%	-0.98%
inTEST	2.33%	5.31%	3.42%

Summary

inTEST beats Frequency Electronics on 11 of the 16 factors compared between the two stocks.

How does inTEST compare to Syntec Optics?

Syntec Optics (NASDAQ:OPTX) and inTEST (NYSE:INTT) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

inTEST has a net margin of 2.33% compared to Syntec Optics' net margin of -10.95%. inTEST's return on equity of 5.31% beat Syntec Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syntec Optics	-10.95%	-30.86%	-12.35%
inTEST	2.33%	5.31%	3.42%

inTEST has a consensus price target of $19.00, suggesting a potential upside of 37.88%. Given inTEST's stronger consensus rating and higher possible upside, analysts plainly believe inTEST is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Syntec Optics had 2 more articles in the media than inTEST. MarketBeat recorded 5 mentions for Syntec Optics and 3 mentions for inTEST. Syntec Optics' average media sentiment score of 0.92 beat inTEST's score of 0.81 indicating that Syntec Optics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syntec Optics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
inTEST	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

inTEST has higher revenue and earnings than Syntec Optics. Syntec Optics is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syntec Optics	$27.53M	10.32	-$1.79M	-$0.08	N/A
inTEST	$121.07M	1.43	$9.34M	$0.04	344.50

63.2% of inTEST shares are held by institutional investors. 0.8% of Syntec Optics shares are held by company insiders. Comparatively, 5.2% of inTEST shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Syntec Optics has a beta of -0.86, indicating that its stock price is 186% less volatile than the broader market. Comparatively, inTEST has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Summary

inTEST beats Syntec Optics on 13 of the 16 factors compared between the two stocks.

How does inTEST compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and inTEST (NYSE:INTT) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

inTEST has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$86.26M	3.77	-$74.90M	$0.20	4.17
inTEST	$121.07M	1.43	$9.34M	$0.04	344.50

Standard BioTools presently has a consensus target price of $1.35, indicating a potential upside of 62.03%. inTEST has a consensus target price of $19.00, indicating a potential upside of 37.88%. Given Standard BioTools' higher probable upside, analysts clearly believe Standard BioTools is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Standard BioTools has a net margin of 73.46% compared to inTEST's net margin of 2.33%. inTEST's return on equity of 5.31% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
inTEST	2.33%	5.31%	3.42%

In the previous week, Standard BioTools had 5 more articles in the media than inTEST. MarketBeat recorded 8 mentions for Standard BioTools and 3 mentions for inTEST. Standard BioTools' average media sentiment score of 0.83 beat inTEST's score of 0.81 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
inTEST	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Standard BioTools has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, inTEST has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 63.2% of inTEST shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Comparatively, 5.2% of inTEST shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

inTEST beats Standard BioTools on 9 of the 16 factors compared between the two stocks.

How does inTEST compare to Prenetics Global?

Prenetics Global (NASDAQ:PRE) and inTEST (NYSE:INTT) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 63.2% of inTEST shares are held by institutional investors. 7.8% of Prenetics Global shares are held by company insiders. Comparatively, 5.2% of inTEST shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

inTEST has a net margin of 2.33% compared to Prenetics Global's net margin of -62.45%. inTEST's return on equity of 5.31% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-62.45%	-20.33%	-15.42%
inTEST	2.33%	5.31%	3.42%

Prenetics Global currently has a consensus price target of $34.25, indicating a potential upside of 82.76%. inTEST has a consensus price target of $19.00, indicating a potential upside of 37.88%. Given Prenetics Global's stronger consensus rating and higher possible upside, research analysts clearly believe Prenetics Global is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Prenetics Global had 2 more articles in the media than inTEST. MarketBeat recorded 5 mentions for Prenetics Global and 3 mentions for inTEST. inTEST's average media sentiment score of 0.81 beat Prenetics Global's score of 0.41 indicating that inTEST is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prenetics Global	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
inTEST	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prenetics Global has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, inTEST has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

inTEST has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$120.07M	2.63	-$37.71M	-$4.58	N/A
inTEST	$121.07M	1.43	$9.34M	$0.04	344.50

Summary

inTEST beats Prenetics Global on 10 of the 16 factors compared between the two stocks.

Get inTEST News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTT vs. The Competition

Export

Metric	inTEST	Instruments to measure electricity Industry	Computer Sector	NYSE Exchange
Market Cap	$173.15M	$86.60M	$37.13B	$23.48B
Dividend Yield	N/A	N/A	3.17%	4.20%
P/E Ratio	59.92	59.92	76.44	30.75
Price / Sales	1.43	0.72	592.83	160.30
Price / Cash	5.75	5.75	44.48	31.69
Price / Book	1.74	1.74	9.07	4.73
Net Income	$9.34M	-$2.88M	$1.07B	$1.07B
7 Day Performance	2.53%	2.53%	-1.81%	-0.45%
1 Month Performance	-22.93%	-22.93%	-2.70%	0.72%
1 Year Performance	79.19%	79.19%	133.84%	14.09%

inTEST Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTT inTEST	2.1211 of 5 stars	$13.78 -6.3%	$19.00 +37.9%	+90.3%	$173.15M	$121.07M	59.92	320	News Coverage
CTKB Cytek Biosciences	2.3809 of 5 stars	$4.62 +2.4%	$5.69 +23.1%	+33.9%	$582.43M	$201.49M	N/A	500	News Coverage Positive News
FEIM Frequency Electronics	1.158 of 5 stars	$58.93 +8.1%	$43.67 -25.9%	+171.4%	$536.39M	$69.81M	78.57	200
OPTX Syntec Optics	0.1749 of 5 stars	$8.20 -1.0%	N/A	+210.6%	$333.52M	$28.08M	N/A	3	News Coverage
LAB Standard BioTools	3.6991 of 5 stars	$0.84 -1.3%	$1.35 +61.1%	-43.3%	$331.34M	$85.33M	4.19	620	Positive News Analyst Upgrade Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INTT) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

inTEST (INTT) Competitors

INTT vs. CTKB, FEIM, OPTX, LAB, and PRE

How does inTEST compare to Cytek Biosciences?

Summary

How does inTEST compare to Frequency Electronics?

Summary

How does inTEST compare to Syntec Optics?

Summary

How does inTEST compare to Standard BioTools?

Summary

How does inTEST compare to Prenetics Global?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTT vs. The Competition

inTEST Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

inTEST (INTT) Competitors

INTT vs. CTKB, FEIM, OPTX, LAB, and PRE

How does inTEST compare to Cytek Biosciences?

Which has higher valuation & earnings, INTT or CTKB?

Is INTT or CTKB more profitable?

Do analysts recommend INTT or CTKB?

Do insiders and institutionals believe in INTT or CTKB?

Which has more volatility and risk, INTT or CTKB?

Does the media prefer INTT or CTKB?

Summary

How does inTEST compare to Frequency Electronics?

Do insiders & institutionals believe in FEIM or INTT?

Does the media refer more to FEIM or INTT?

Do analysts recommend FEIM or INTT?

Which has more volatility & risk, FEIM or INTT?

Which has better valuation & earnings, FEIM or INTT?

Is FEIM or INTT more profitable?

Summary

How does inTEST compare to Syntec Optics?

Is OPTX or INTT more profitable?

Do analysts recommend OPTX or INTT?

Does the media refer more to OPTX or INTT?

Which has preferable earnings and valuation, OPTX or INTT?

Do institutionals and insiders believe in OPTX or INTT?

Which has more risk and volatility, OPTX or INTT?

Summary

How does inTEST compare to Standard BioTools?

Which has higher earnings and valuation, LAB or INTT?

Do analysts rate LAB or INTT?

Is LAB or INTT more profitable?

Does the media favor LAB or INTT?

Which has more volatility & risk, LAB or INTT?

Do insiders and institutionals have more ownership in LAB or INTT?

Summary

How does inTEST compare to Prenetics Global?

Do insiders & institutionals have more ownership in PRE or INTT?

Is PRE or INTT more profitable?

Do analysts recommend PRE or INTT?

Does the media favor PRE or INTT?

Which has more volatility & risk, PRE or INTT?

Which has preferable valuation & earnings, PRE or INTT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTT vs. The Competition

inTEST Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools